Curocell Statistics

Total Valuation

Curocell has a market cap or net worth of KRW 533.46 billion. The enterprise value is 565.45 billion.

Market Cap	533.46B
Enterprise Value	565.45B

Important Dates

The last earnings date was Friday, March 27, 2026.

Earnings Date	Mar 27, 2026
Ex-Dividend Date	n/a

Share Statistics

Curocell has 15.18 million shares outstanding. The number of shares has increased by 2.50% in one year.

Current Share Class	15.18M
Shares Outstanding	15.18M
Shares Change (YoY)	+2.50%
Shares Change (QoQ)	+0.41%
Owned by Insiders (%)	32.21%
Owned by Institutions (%)	5.44%
Float	10.28M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	106.16
P/TBV Ratio	290.02
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-12.21
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-18.66

Financial Position

The company has a current ratio of 0.33, with a Debt / Equity ratio of 11.28.

Current Ratio	0.33
Quick Ratio	0.25
Debt / Equity	11.28
Debt / EBITDA	n/a
Debt / FCF	-1.87
Interest Coverage	-7.99

Financial Efficiency

Return on equity (ROE) is -268.60% and return on invested capital (ROIC) is -35.31%.

Return on Equity (ROE)	-268.60%
Return on Assets (ROA)	-24.96%
Return on Invested Capital (ROIC)	-35.31%
Return on Capital Employed (ROCE)	-285.61%
Weighted Average Cost of Capital (WACC)	10.33%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +19.36% in the last 52 weeks. The beta is 1.18, so Curocell's price volatility has been higher than the market average.

Beta (5Y)	1.18
52-Week Price Change	+19.36%
50-Day Moving Average	51,221.00
200-Day Moving Average	45,040.75
Relative Strength Index (RSI)	26.00
Average Volume (20 Days)	249,291

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	-19.60M
Operating Income	-36.29B
Pretax Income	-46.31B
Net Income	-46.31B
EBITDA	-30.17B
EBIT	-36.29B
Earnings Per Share (EPS)	-3,232.17

Full Income Statement

Balance Sheet

The company has 24.16 billion in cash and 56.68 billion in debt, with a net cash position of -32.52 billion or -2,142.51 per share.

Cash & Cash Equivalents	24.16B
Total Debt	56.68B
Net Cash	-32.52B
Net Cash Per Share	-2,142.51
Equity (Book Value)	5.03B
Book Value Per Share	348.18
Working Capital	-64.68B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -29.99 billion and capital expenditures -313.23 million, giving a free cash flow of -30.31 billion.

Operating Cash Flow	-29.99B
Capital Expenditures	-313.23M
Depreciation & Amortization	6.12B
Net Borrowing	42.46B
Free Cash Flow	-30.31B
FCF Per Share	-1,996.93

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Curocell does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.50%
Shareholder Yield	-2.50%
Earnings Yield	-8.68%
FCF Yield	-5.68%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1